![W. Wendell Cheatham](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
W. Wendell Cheatham
Geen lopende functies
77 jaar
Health Technology
Profiel
W.
Wayman Wendell Cheatham has been Corporate Vice President of MannKind Corp.
since August 2002 and Chief Medical Officer since November 2004.
From April 1999 to August 2002, he was Vice President of Medical & Regulatory Affairs for Takeda Pharmaceuticals North America, Inc. and Director of Medical Affairs for Novo Nordisk Pharmaceuticals North America, Inc. from August 1996 to April 1999.
Currently, Dr. Cheatham is a Director of the American Diabetes Association.
He received an MD from the Pennsylvania State University College of Medicine in 1975.
Eerdere bekende functies van W. Wendell Cheatham
| Bedrijven | Functie | Einde |
|---|---|---|
| MANNKIND CORPORATION | Hoofd Techniek/Wetenschap/O&O | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
MannKind Corp.
 MannKind Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes therapeutic products | Health Technology |
